Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma

Antoni Ribas, MD, PhD
Published Online: Monday, Jun 03, 2013



Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

Clinically meaningful activity was observed in a substantial number of patients in the trial, Ribas explains. The overall response rate by RECIST criteria was 38% with 90% of patients experiencing durable responses. At the highest dose, response was 52%. Most of the adverse events with lambrolizumab were minimal, Ribas suggests.

<<< View more from the 2013 ASCO Annual Meeting



Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

Clinically meaningful activity was observed in a substantial number of patients in the trial, Ribas explains. The overall response rate by RECIST criteria was 38% with 90% of patients experiencing durable responses. At the highest dose, response was 52%. Most of the adverse events with lambrolizumab were minimal, Ribas suggests.

<<< View more from the 2013 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Skin Cancer and Other Cutaneous MalignanciesDec 23, 20162.0
Combination Therapy for Metastatic MelanomaJan 21, 20171.0
Publication Bottom Border
Border Publication